Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Howard Woolley, MASHoward Woolley is a philanthropist with ...
-
The Comprehensive Sickle Cell Center at Children’s Hospital of PhiladelphiaThe Comprehensive Sickle Cell Center at ...
-
Webinar Series: Sickle Cell Science: Path to Progress – Serving the Sickle Cell Disease Community Here and Abr...To commemorate Sickle Cell Awareness Mon...
-
Lakshmanan Krishnamurti, MDDr. Krishnamurti graduated from the Arme...
-
Emergency Medicine Management of Sickle Cell Disease Complications: An Evidence-Based UpdateBACKGROUND: Sickle cell disease (SCD) af...
-
Children’s Hospital Oakland Research InstituteDuring our first 50 years, Children’s ...
-
Caries prevalence and impact on oral health-related quality of life in children with sickle cell disease: cross-sect...BACKGROUND: Children with sickle cell di...
